Cargando…

伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析

OBJECTIVE: To cross-sectionally analyze the clinical characteristics of primary antiphospholipid syndrome (PAPS) patients with thrombocytopenia, risk factors associated with thrombocytopenia, and risk of symptom recurrence in these patients. METHODS: The inpatients with PAPS were retrospectively ana...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957258/
https://www.ncbi.nlm.nih.gov/pubmed/33677866
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.007
_version_ 1783664617831006208
collection PubMed
description OBJECTIVE: To cross-sectionally analyze the clinical characteristics of primary antiphospholipid syndrome (PAPS) patients with thrombocytopenia, risk factors associated with thrombocytopenia, and risk of symptom recurrence in these patients. METHODS: The inpatients with PAPS were retrospectively analyzed in Peking Union Medical College Hospital from 2009 to 2019. Using the collected clinical and laboratory data, the clinical characteristics and risk of symptom recurrence in the PAPS patients with thrombocytopenia were compared with those in the PAPS patients with normal platelet counts. Univariate and multivariate logistic regression analyses were performed to screen the risk factors for thrombocytopenia. RESULTS: In this study, 127 patients with PAPS were enrolled, of which 36 (28.3%) had thrombocytopenia, with a median age of 38 years, and 63.9% were female. In the thrombocytopenia group, the average platelet count was (58.9±27.0) ×10(9)/L, and the prevalence of thrombosis and morbid pregnancy was not significantly different from that in the normal platelet group. However, the thrombocytopenia group had higher incidence rate of autoimmune hemolytic anemia (19.4% vs 3.3%), livedo reticularis (16.7% vs 3.3%), chronic kidney disease (25% vs 8.8%) and antiphospholipid antibodies triple positiveness (61.1% vs 37.4%), lower complement levels (C3 of 0.87 g/L vs 1.07 g/L, C4 of 0.12 g/L vs 0.18 g/L, P<0.05), and higher adjusted Global APS Score (median score of 13 vs 9, P=0.037) than the normal platelet group. In multivariate logistic regression analysis, hypocomplementemia (OR value 5.032, 95% CI 3.118–22.095) is an independent risk factor for thrombocytopenia. CONCLUSION: In patients with PAPS, thrombocytopenia is mostly mild to moderate. Hypocomplementemia may be the independent risk factor for thrombocytopenia in PAPS patients. The PAPS patients with thrombocytopenia may have a higher risk of symptom recurrence.
format Online
Article
Text
id pubmed-7957258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-79572582021-03-15 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To cross-sectionally analyze the clinical characteristics of primary antiphospholipid syndrome (PAPS) patients with thrombocytopenia, risk factors associated with thrombocytopenia, and risk of symptom recurrence in these patients. METHODS: The inpatients with PAPS were retrospectively analyzed in Peking Union Medical College Hospital from 2009 to 2019. Using the collected clinical and laboratory data, the clinical characteristics and risk of symptom recurrence in the PAPS patients with thrombocytopenia were compared with those in the PAPS patients with normal platelet counts. Univariate and multivariate logistic regression analyses were performed to screen the risk factors for thrombocytopenia. RESULTS: In this study, 127 patients with PAPS were enrolled, of which 36 (28.3%) had thrombocytopenia, with a median age of 38 years, and 63.9% were female. In the thrombocytopenia group, the average platelet count was (58.9±27.0) ×10(9)/L, and the prevalence of thrombosis and morbid pregnancy was not significantly different from that in the normal platelet group. However, the thrombocytopenia group had higher incidence rate of autoimmune hemolytic anemia (19.4% vs 3.3%), livedo reticularis (16.7% vs 3.3%), chronic kidney disease (25% vs 8.8%) and antiphospholipid antibodies triple positiveness (61.1% vs 37.4%), lower complement levels (C3 of 0.87 g/L vs 1.07 g/L, C4 of 0.12 g/L vs 0.18 g/L, P<0.05), and higher adjusted Global APS Score (median score of 13 vs 9, P=0.037) than the normal platelet group. In multivariate logistic regression analysis, hypocomplementemia (OR value 5.032, 95% CI 3.118–22.095) is an independent risk factor for thrombocytopenia. CONCLUSION: In patients with PAPS, thrombocytopenia is mostly mild to moderate. Hypocomplementemia may be the independent risk factor for thrombocytopenia in PAPS patients. The PAPS patients with thrombocytopenia may have a higher risk of symptom recurrence. Editorial office of Chinese Journal of Hematology 2021-01 /pmc/articles/PMC7957258/ /pubmed/33677866 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.007 Text en 2021年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title_full 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title_fullStr 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title_full_unstemmed 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title_short 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
title_sort 伴血小板减少原发性抗磷脂综合征的临床特征及相关因素分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957258/
https://www.ncbi.nlm.nih.gov/pubmed/33677866
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.007
work_keys_str_mv AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī
AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī
AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī
AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī
AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī
AT bànxuèxiǎobǎnjiǎnshǎoyuánfāxìngkànglínzhīzōnghézhēngdelínchuángtèzhēngjíxiāngguānyīnsùfēnxī